Comparison of two modalities for the treatment of warts - digoxin and furosemide vs protein purified derivative

A Comparitive Study of intralesional Combined Digoxin and furosemide versus Tuberculin purified protein derivative in the treatment of warts - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058907

Enrollment

Registered

2023-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Combined Intralesional Digoxin and Furosemide VS Tibercullin PPD: Given every 3 weeks till 3 months Intervention2: Intralesional Digoxin and Furosemide are potassium channel blockers ,

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with multiple viral warts and all clinical varieties are included in the study 2.Age between 18 – 65 years with no concurrent systemic or topical treatment for warts.

Exclusion criteria

Exclusion criteria: 1. Patients under any systemic or topical treatment of warts for the last four weeks 2. Patients with a past history of an allergic response to MMR or any other vaccine. 3. Immunosuppressed patients, patients with past history of TB and/or active TB. 4. Pregnant or lactating women 5. Patients having a past history of asthma, allergic skin disorders or convulsions 6. Patients with keloidal tendency/cardiac abnormality

Design outcomes

Primary

Measure	Time frame
Reduction in number & size of the warts .Timepoint: Every 2 weeks	—

Secondary

Measure	Time frame
Complete clearance of wartsTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr MShiva saadhvi

Sri Devaraj Urs Medical college

yeshitss1@gmail.com9448316136

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026